An Endogenous miRNA-Initiated Hybridization Chain Reaction and Subsequent DNAzyme Activation for Cellular Theranostics

Quan, Ke; Wang, Jiaoli; Li, Jing; Wang, Kemin; Huang, Jin

doi:10.31635/ccschem.021.202101418

Cited by 10 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a highly repetitive DNAzyme triggered by miR‐21 has been reported for catalytic cleavage of EGR‐1 mRNA. [ 189 ] The nanostructure could perform amplified miR‐21 imaging in living cells and effectively inhibit the proliferation of cancer cells with high specificity, thereby generating sensitive diagnostic signals and accurate therapeutic effects. This work, an example of miRNA‐triggered intracellular DNAzyme self‐assembly, demonstrated the uniqueness and advancement of miRNA‐responsive payload release.…”

Section: Dnazymes In Advanced Gene Therapymentioning

confidence: 99%

Therapeutic DNAzymes: From Structure Design to Clinical Applications

et al. 2023

View full text Add to dashboard Cite

Therapeutic DNAzymes have unceasingly intrigued the scientific community owing to their prosperous gene regulation capability. The efficacy of DNAzymes against many types of diseases has been extensively studied for over two decades. However, the high expectations for DNAzymes are still not translated to the clinic because of their low effectiveness in vivo. Over the last five years, several aspects have been considered to optimize DNAzyme‐integrated therapeutics, including structural stability, mechanism exploration, cell internalization rate, cofactor activation, and off‐target effects. Hence, this review first discusses the early monotherapy and structural design of DNAzymes. Subsequently, the latest modes of action are reviewed, followed by an elaboration on structural stabilization strategies considering the catalytic core and substrate‐binding arms. DNAzyme‐based synergistic therapy is then examined, highlighting responsive carrier construction, synergistic effects, the latest discovered advanced functions, and off‐target concerns. Beyond this, key clinical advances in DNAzyme‐based therapy are elucidated by showcasing clinical progress. Finally, future trends and development challenges for DNAzyme‐powered therapeutics in the coming years are discussed in detail.

show abstract

Section: Dnazymes In Advanced Gene Therapymentioning

confidence: 99%

Therapeutic DNAzymes: From Structure Design to Clinical Applications

et al. 2023

View full text Add to dashboard Cite

show abstract

“…6,9,10 Owing to their compact size (19-24 nucleotides) and comparatively more straightforward biological processes than proteins and DNA, 11,12 miRNAs are considered valuable biomarkers for disease diagnosis and therapy targets. [13][14][15][16][17] However, traditional miRNA analysis methods, such as those involving uorescent hybridization probes (including electrochemical [18][19][20] and quantitative real-time polymerase chain reaction (qPCR) 21 approaches) and MS2 RNA binding protein-uorescent protein systems, [22][23][24][25][26][27] have limitations in terms of probe degradation, delivery challenges, complex kinetics, [21][22][23][24] and inability to visualize multiple miRNA targets in a single cell, hindering their effectiveness. 28 Besides, the presence of homologous sequences and the low expression levels of miRNAs in living cells pose challenges to their detection.…”

Section: Introductionmentioning

confidence: 99%